Literature DB >> 23858334

Bisphosphonate drug holiday: who, when and how long.

Dima L Diab1, Nelson B Watts.   

Abstract

Bisphosphonates have been widely used in the treatment of osteoporosis with robust data from numerous placebo-controlled trials demonstrating efficacy in fracture risk reduction over 3-5 years of treatment. Although bisphosphonates are generally safe and well tolerated, concerns have emerged about adverse effects related to long-term use. For most patients with osteoporosis, the benefits of treatment outweigh the risks. Because these agents accumulate in bone with some persistent antifracture efficacy after therapy is stopped, it is reasonable to consider a 'drug holiday.' There is considerable controversy regarding the optimal duration of therapy and the length of the holiday, both of which should be based on individual assessments of risk and benefit.

Entities:  

Keywords:  bisphosphonates; drug holidays; fractures; osteoporosis

Year:  2013        PMID: 23858334      PMCID: PMC3707342          DOI: 10.1177/1759720X13477714

Source DB:  PubMed          Journal:  Ther Adv Musculoskelet Dis        ISSN: 1759-720X            Impact factor:   5.346


  18 in total

1.  Prolonged bisphosphonate release after treatment in children.

Authors:  Socrates E Papapoulos; Serge C L M Cremers
Journal:  N Engl J Med       Date:  2007-03-08       Impact factor: 91.245

2.  Bisphosphonates for osteoporosis--where do we go from here?

Authors:  Marcea Whitaker; Jia Guo; Theresa Kehoe; George Benson
Journal:  N Engl J Med       Date:  2012-05-09       Impact factor: 91.245

Review 3.  Bisphosphonates in the treatment of osteoporosis.

Authors:  Dima L Diab; Nelson B Watts
Journal:  Endocrinol Metab Clin North Am       Date:  2012-06-09       Impact factor: 4.741

Review 4.  Bisphosphonates for postmenopausal osteoporosis.

Authors:  Richard Eastell; Jennifer S Walsh; Nelson B Watts; Ethel Siris
Journal:  Bone       Date:  2011-02-22       Impact factor: 4.398

5.  Does osteoporosis therapy invalidate FRAX for fracture prediction?

Authors:  William D Leslie; Lisa M Lix; Helena Johansson; Anders Oden; Eugene McCloskey; John A Kanis
Journal:  J Bone Miner Res       Date:  2012-06       Impact factor: 6.741

Review 6.  Bone safety of long-term bisphosphonate treatment.

Authors:  Gideon Rodan; Alfred Reszka; Ellis Golub; René Rizzoli
Journal:  Curr Med Res Opin       Date:  2004-08       Impact factor: 2.580

7.  Seven years of treatment with risedronate in women with postmenopausal osteoporosis.

Authors:  D D Mellström; O H Sörensen; S Goemaere; C Roux; T D Johnson; A A Chines
Journal:  Calcif Tissue Int       Date:  2004-10-07       Impact factor: 4.333

Review 8.  Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy.

Authors:  R G G Russell; N B Watts; F H Ebetino; M J Rogers
Journal:  Osteoporos Int       Date:  2008-06       Impact factor: 4.507

9.  Fracture risk remains reduced one year after discontinuation of risedronate.

Authors:  N B Watts; A Chines; W P Olszynski; C D McKeever; M R McClung; X Zhou; A Grauer
Journal:  Osteoporos Int       Date:  2007-10-16       Impact factor: 4.507

10.  The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT).

Authors:  Dennis M Black; Ian R Reid; Steven Boonen; Christina Bucci-Rechtweg; Jane A Cauley; Felicia Cosman; Steven R Cummings; Trisha F Hue; Kurt Lippuner; Peter Lakatos; Ping Chung Leung; Zulema Man; Ruvie Lou Maria Martinez; Monique Tan; Mary Ellen Ruzycky; Guoqin Su; Richard Eastell
Journal:  J Bone Miner Res       Date:  2012-02       Impact factor: 6.741

View more
  23 in total

1.  Bisphosphonate drug holidays: we reap what we sow.

Authors:  S L Silverman; J D Adachi; E Dennison
Journal:  Osteoporos Int       Date:  2015-12-14       Impact factor: 4.507

Review 2.  The next step after anti-osteoporotic drug discontinuation: an up-to-date review of sequential treatment.

Authors:  Núria Guañabens; María Jesús Moro-Álvarez; Enrique Casado; Josep Blanch-Rubió; Carlos Gómez-Alonso; Guillermo Martínez Díaz-Guerra; Javier Del Pino-Montes; Carmen Valero Díaz de Lamadrid; Pilar Peris; Manuel Muñoz-Torres
Journal:  Endocrine       Date:  2019-04-08       Impact factor: 3.633

3.  Atypical femur fracture during bisphosphonate drug holiday: a case series.

Authors:  A J Lovy; S M Koehler; A Keswani; D Joseph; R Hasija; R Ghillani
Journal:  Osteoporos Int       Date:  2015-04-02       Impact factor: 4.507

4.  Rescue bisphosphonate treatment of alveolar bone improves extraction socket healing and reduces osteonecrosis in zoledronate-treated mice.

Authors:  Akishige Hokugo; Keiichi Kanayama; Shuting Sun; Kenzo Morinaga; Yujie Sun; QingQing Wu; Hodaka Sasaki; Hiroko Okawa; Courtney Evans; Frank H Ebetino; Mark W Lundy; Keivan Sadrerafi; Charles E McKenna; Ichiro Nishimura
Journal:  Bone       Date:  2019-03-26       Impact factor: 4.398

5.  Effects of discontinuing oral bisphosphonate treatments for postmenopausal osteoporosis on bone turnover markers and bone density.

Authors:  K E Naylor; M Bradburn; M A Paggiosi; F Gossiel; N F A Peel; E V McCloskey; J S Walsh; R Eastell
Journal:  Osteoporos Int       Date:  2018-03-10       Impact factor: 4.507

6.  Hip fracture trends in the United States, 2002 to 2015.

Authors:  E Michael Lewiecki; N C Wright; J R Curtis; E Siris; R F Gagel; K G Saag; A J Singer; P M Steven; R A Adler
Journal:  Osteoporos Int       Date:  2017-12-27       Impact factor: 4.507

Review 7.  The current situation in the approach to osteoporosis in older adults in Turkey: areas in need of improvement with a model for other populations.

Authors:  Gulistan Bahat; Nezahat Muge Catikkas; Dilek Gogas Yavuz; Pinar Borman; Rengin Guzel; Jean Yves Reginster
Journal:  Arch Osteoporos       Date:  2021-11-30       Impact factor: 2.617

8.  Does Drug Holiday Affect Jaw Trabeculation in Medication Related Osteonecrosis of the Jaw? - A Pilot Study.

Authors:  Niranzena Panneer-Selvam; Abrar Alamoudi; Joseph Riley Iii; Joseph Katz
Journal:  J Clin Exp Dent       Date:  2022-04-01

Review 9.  Osteoporosis, bone mineral density and CKD-MBD: treatment considerations.

Authors:  Jordi Bover; Lucía Bailone; Víctor López-Báez; Silvia Benito; Paola Ciceri; Andrea Galassi; Mario Cozzolino
Journal:  J Nephrol       Date:  2017-04-21       Impact factor: 3.902

10.  Local RANKL delivery improves socket healing in bisphosphonate treated rats.

Authors:  Akrivoula Soundia; Danny Hadaya; Yee Chau; Ioannis Gkouveris; Olga Bezouglaia; Sarah Dry; Flavia Pirih; Tara Aghaloo; Sotirios Tetradis
Journal:  Bone       Date:  2021-04-07       Impact factor: 4.626

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.